An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 May 2020.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated